Immune checkpoint blockade (ICB) has reshaped the treatment of advanced non-small cell lung cancer (NSCLC), yet durable benefit remains limited to a subset of patients. One major pattern of resistance is immune exclusion, in which CD8+ T cells accumulate in stromal regions but fail to penetrate tumor nests. Here, using...
J. Guégan, Benjamin Bonhomme, F. Peyraud et al.· Signal Transduction and Targ...· 0 citations
BACKGROUND
Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...
F. Pecci, Xinan Wang, Valentina Santo et al.· Journal of Thoracic Oncology· 0 citations
A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
N. Florez, S. Patel, R. Salgia et al.· Cancer· 1 citation
A deeper understanding of the brain metastatic ecosystem may enable the development of more effective, biology-driven therapeutic approaches for NSCLC BM.
Marcel Kemper, Lea Reitnauer, A. Leonetti et al.· Cancer Biome and Targeted Th...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.